Transthyretin Amyloidosis with Polyneuropathy
📧 Sign up to get email alerts when something new happens for Transthyretin Amyloidosis with Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-17FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for VYNDAMAX (tafamidis) from Pfizer Laboratories Div Pfizer Inc, typically to support labeling …
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis [Phase 3]
Phase 3 trial evaluating safety and efficacy of Fx-1006A in transthyretin amyloidosis with polyneuropathy (ATTR-PN) has completed.
-
CLINICAL_TRIALS trial_result · 2012-12-17Clinical Trial Update: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis [Phase 2]
Phase 2 clinical trial of Fx-1006A in non-V30M transthyretin amyloidosis with polyneuropathy evaluated for transthyretin stabilization and c…